TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

SODIUM FERRIC GLUCONATE COMPLEX
Hematology Approved 2011-03-31
1
Indication
--
Phase 3 Trials
14
Years on Market

Details

Status
Prescription
First Approved
2011-03-31
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: SODIUM FERRIC GLUCONATE COMPLEX

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE Approval History

Loading approval history...

What SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE Treats

2 indications

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE is approved for 2 conditions since its original approval in 2011. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Iron Deficiency Anemia
  • Chronic Kidney Disease
Source: FDA Label

Drugs Similar to SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AURYXIA
FERRIC CITRATE
2 shared
KERYX BIOPHARMS
Shared indications:
Chronic Kidney DiseaseIron Deficiency Anemia
FERAHEME
FERUMOXYTOL
2 shared
COVIS
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
FERRLECIT
SODIUM FERRIC GLUCONATE COMPLEX
2 shared
Sanofi
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
FERUMOXYTOL
FERUMOXYTOL
2 shared
Novartis
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
INJECTAFER
FERRIC CARBOXYMALTOSE
2 shared
AM REGENT
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
IRON SUCROSE
IRON SUCROSE
2 shared
Novartis
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
MONOFERRIC
FERRIC DERISOMALTOSE
2 shared
PHARMACOSMOS
Shared indications:
Iron Deficiency AnemiaChronic Kidney Disease
DOXERCALCIFEROL
DOXERCALCIFEROL
1 shared
CAPLIN
Shared indications:
Chronic Kidney Disease
EPOGEN/PROCRIT
EPOETIN ALFA
1 shared
Amgen
Shared indications:
Chronic Kidney Disease
FARXIGA
DAPAGLIFLOZIN
1 shared
AstraZeneca
Shared indications:
Chronic Kidney Disease
FUROSCIX
FUROSEMIDE
1 shared
SCPHARMACEUTICALS
Shared indications:
Chronic Kidney Disease
INPEFA
SOTAGLIFLOZIN
1 shared
LEXICON PHARMS INC
Shared indications:
Chronic Kidney Disease
JARDIANCE
EMPAGLIFLOZIN
1 shared
Boehringer Ingelheim
Shared indications:
Chronic Kidney Disease
KERENDIA
FINERENONE
1 shared
Bayer
Shared indications:
Chronic Kidney Disease
KORSUVA
DIFELIKEFALIN ACETATE
1 shared
VIFOR INTL
Shared indications:
Chronic Kidney Disease
MIRCERA
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
1 shared
HOFFMAN-LA ROCHE
Shared indications:
Chronic Kidney Disease
PARSABIV
ETELCALCETIDE
1 shared
KAI PHARMS INC
Shared indications:
Chronic Kidney Disease
RAYALDEE
CALCIFEDIOL
1 shared
EIRGEN
Shared indications:
Chronic Kidney Disease
RENVELA
SEVELAMER CARBONATE
1 shared
Sanofi
Shared indications:
Chronic Kidney Disease
RETACRIT
EPOETIN ALFA-EPBX
1 shared
Pfizer
Shared indications:
Chronic Kidney Disease
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE FDA Label Details

Pro

Indications & Usage

Sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. Sodium ferric gluconate complex in sucrose injection is an iron replacement product for treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.